Hudson Edge Investment Partners Inc. Grows Stake in Bristol Myers Squibb Company $BMY

Hudson Edge Investment Partners Inc. increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 10.2% during the third quarter, Holdings Channel.com reports. The institutional investor owned 144,968 shares of the biopharmaceutical company’s stock after buying an additional 13,394 shares during the quarter. Hudson Edge Investment Partners Inc.’s holdings in Bristol Myers Squibb were worth $6,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Trifecta Capital Advisors LLC purchased a new position in Bristol Myers Squibb in the second quarter valued at $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter worth $25,000. Harbor Capital Advisors Inc. raised its holdings in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares during the last quarter. REAP Financial Group LLC lifted its position in Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 428 shares in the last quarter. Finally, DHJJ Financial Advisors Ltd. grew its holdings in shares of Bristol Myers Squibb by 51.9% in the second quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 267 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Citigroup reaffirmed a “neutral” rating and issued a $53.00 target price (up previously from $45.00) on shares of Bristol Myers Squibb in a research report on Wednesday, January 7th. Scotiabank reissued a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Morgan Stanley reiterated an “underweight” rating and set a $37.00 target price (up previously from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, HSBC reaffirmed a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Seven equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $56.86.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY to a Buy, saying the stock’s risk/reward is skewed to the upside; the call likely attracted buyers and underpins bullish sentiment. Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock
• Positive Sentiment: BMY announced a partnership with Microsoft to apply AI for earlier lung-cancer detection — a strategic move that can expand diagnostic reach, support earlier use of BMY oncology assets, and generates positive sentiment around future revenue/health?tech synergies. Bristol Myers partners with Microsoft for AI-driven lung cancer detection
• Positive Sentiment: The UK is set to adopt a new use for Opdivo in early-stage lung cancer, increasing commercial upside and supporting BMY’s oncology revenue profile. New Opdivo use in early lung cancer set for adoption in UK
• Positive Sentiment: Street bulls (Leerink) highlight ample pipeline optionality for 2026, reinforcing longer?term growth expectations and supporting multiple expansion. Leerink Bullish on Bristol-Myers Squibb Company (BMY) Amid Ample Pipeline Optionality in 2026
• Neutral Sentiment: Zacks issued small, mixed EPS estimate tweaks (minor upward and downward adjustments across quarters/years) — not a major directional catalyst but worth monitoring for guidance revisions. Zacks Research EPS estimate updates for BMY
• Neutral Sentiment: Ongoing clinical updates (KarXT long?term urological safety study) and routine mentions on shows like CNBC’s Fast Money keep BMY in the newsflow; these items sustain attention but are incremental. KarXT safety study update
• Negative Sentiment: Separately, a recent ~3% pullback and commentary about institutional owners potentially taking action highlight near?term selling pressure and remind investors of volatility risk. Bristol-Myers Squibb Company’s (NYSE:BMY) recent 3.0% pullback adds to one-year year losses, institutional owners may take drastic measures

Bristol Myers Squibb Price Performance

BMY opened at $54.42 on Thursday. The company has a market capitalization of $110.78 billion, a P/E ratio of 18.38, a PEG ratio of 0.17 and a beta of 0.29. The company has a 50-day moving average of $52.28 and a 200-day moving average of $48.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same period in the prior year, the company earned $1.80 earnings per share. The business’s revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. Bristol Myers Squibb’s payout ratio is 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.